Immuno-comparative screening of adult-derived human liver stem/progenitor cells for immune-inflammatory-associated molecules.
Cell therapy
Immunological screening
Liver
Stem/progenitor cells
Tissue repair
Journal
Inflammation research : official journal of the European Histamine Research Society ... [et al.]
ISSN: 1420-908X
Titre abrégé: Inflamm Res
Pays: Switzerland
ID NLM: 9508160
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
02
04
2020
accepted:
27
11
2020
revised:
04
11
2020
pubmed:
7
1
2021
medline:
7
10
2021
entrez:
6
1
2021
Statut:
ppublish
Résumé
One of the main challenges in liver cell therapy is the replacement of damaged cells and the induction of a tolerogenic microenvironment to promote graft acceptance by the recipient. Adult-derived human liver stem/progenitor cells (ADHLSCs) are currently evaluated at the clinical levels as a promising pro-regenerative and immune-modulatory tool. The expression profile of several immunological molecules may influence the local immune-inflammatory response and, therefore, modulate the tissue healing process. To increase the quality and safety of ADHLSCs before transplantation requires an appropriate analysis and characterization of their pattern expression of immune-inflammatory-associated molecules. The expression of 27 molecules belonging to T-cell co-stimulatory pathway, CD47 partners, Ikaros family, CD300 family and TNF family were analyzed using flow cytometry. We compared their expression profiles to PBMCs, hepatocytes and ADHLSCs in both expansion and after hepatogenic differentiation culture conditions. This original immuno-comparative screening revealed that liver cell populations do not constitutively present significant immunological pattern compared to PBMCs. Moreover, our findings highlight that neither the expansion nor the hepatogenic differentiation induces the expression of immune-inflammatory molecules. The detailed expression characteristics (percentage of positive cells and median fluorescence intensity) of each molecule were analyzed and presented. By analyzing 27 relevant molecules, our immuno-comparative screening demonstrates that ADHLSCs keep a non-immunogenic profile independent of their expansion or hepatogenic differentiation state. Accordingly, the immunological profile of ADHLSCs seems to support their safe and efficient use in liver tissue therapeutic repair strategy.
Identifiants
pubmed: 33404674
doi: 10.1007/s00011-020-01428-9
pii: 10.1007/s00011-020-01428-9
doi:
Substances chimiques
Antigens, CD
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-239Références
Jadlowiec CC, Taner T. Liver transplantation: current status and challenges. World J Gastroenterol. 2016;22:4438–45.
pubmed: 27182155
pmcid: 4858627
Roskams T. Different types of liver progenitor cells and their niches. J Hepatol. 2006;45:1–4.
pubmed: 16723168
Kwak KA, Cho HJ, Yang JY, Park YS. Current perspectives regarding stem cell-based therapy for liver cirrhosis. Can J Gastroenterol Hepatol. 2018;2018:1–19.
Christ B, Franquesa M, Najimi M, van der Laan LJW, Dahlke MH. Cellular and molecular mechanisms of mesenchymal stem cell actions. Stem Cells Int. 2017;2017:1–2.
Lombard CA, Sana G, LeMaoult J, Najar M, Ravau J, André F, Bouhtit F, Daouya M, Loustau M, Najimi M, Lagneaux L, Carosella ED, Sokal EM. Human hepatocytes and differentiated adult-derived human liver stem/progenitor cells display in vitro immunosuppressive properties mediated, at least in part, through the nonclassical HLA class I molecule HLA-G. J Immunol Res. 2019;2019:1–13.
Bizzaro D, Russo FP, Burra P. New perspectives in liver transplantation: from regeneration to bioengineering. Bioeng (Basel). 2019;6:1–19.
Fayyad-Kazan H, Faour WH, Badran B, Lagneaux L, Najar M. The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria. Inflamm Res. 2016;65:501–10.
pubmed: 26956767
Affolter T, Llewellyn HP, Bartlett DW, Zong Q, Xia S, Torti V, Ji C. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE. 2019;14:1–19.
Najimi M, Khuu DN, Lysy PA, Jazouli N, Abarca J, Sempoux C, Sokal M. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant. 2007;16:717–28.
pubmed: 18019361
Sokal EM. From hepatocytes to stem and progenitor cells for liver regenerative medicine: advances and clinical perspectives. Cell Prolif. 2011;44:39–43.
pubmed: 21481042
pmcid: 6496595
Carpino G, Gaudio E. Cell sources for regenerative medicine of the liver and endoderm organs: strategies and perspectives. Stem Cell Investig. 2016;3:1–5.
Najimi M, Defresne F, Sokal EM. Concise review: updated advances and current challenges in cell therapy for inborn liver metabolic defects. Stem Cells Transl Med. 2016;5:1117–25.
pubmed: 27245366
pmcid: 4954449
Markose D, Kirkland P, Ramachandran P, Henderson NC. Immune cell regulation of liver regeneration and repair. J Immunol Regen Med. 2018;2:1–10.
Najar M, Bouhtit F, Melki R, Afif H, Hamal A, Fahmi H, Merimi M, Lagneaux L. Mesenchymal stromal cell-based therapy: new perspectives and challenges. J Clin Med. 2019;8:1–8.
Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54.
pubmed: 24232253
pmcid: 3849579
Buyl K, Merimi M, Rodrigues RM, Moussa Agha D, Melki R, Vanhaecke T, Bron D, Lewalle P, Meuleman N, Fahmi H, Rogiers V, Lagneaux L, De Kock J, Najar M. The impact of cell-expansion and inflammation on the immune-biology of human adipose tissue-derived mesenchymal stromal cells. J Clin Med. 2020;9:696.
pmcid: 7141238
Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.
pubmed: 11910893
El-Kehdy H, Sargiacomo C, Fayyad-Kazan M, Fayyad-Kazan H, Lombard C, Lagneaux L, Sokal E, Najar M, Najimi M. Immunoprofiling of adult-derived human liver stem/progenitor cells: impact of hepatogenic differentiation and inflammation. Stem Cells Int. 2017;2017:1.
Gaber T, Schönbeck K, Hoff H, Tran CL, Strehl C, Lang A, Ohrndorf S, Pfeiffenberger M, Röhner E, Matziolis G, Burmester GR, Buttgereit F, Hoff P. CTLA-4 mediates inhibitory function of mesenchymal stem/stromal cells. Int J Mol Sci. 2018;19:1–12.
Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:1–17.
Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, Schölmerich J, Hellerbrand C. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol. 2006;45:520–8.
pubmed: 16876901
Lee HJ, Kim SN, Jeon MS, Yi T, Song SU. ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells. Sci Rep. 2017;7:1.
Maeda S, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Hasegawa M. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production. Am J Pathol. 2011;179:2360–9.
pubmed: 21925472
pmcid: 3204021
Dai Z, Nasr IW, Reel M, Deng S, Diggs L, Larsen CP, Rothstein DM, Lakkis FG. Impaired recall of CD8 memory T cells in immunologically privileged tissue. J Immunol. 2005;174(3):1165–70.
pubmed: 15661869
Kwon B. CD137–CD137 Ligand interactions in inflammation. Immune Netw. 2009;9:84–9.
pubmed: 20107537
pmcid: 2803301
Christopeit M, Schendel M, Föll J, Müller LP, Keysser G, Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia. 2008;22:1062–4.
pubmed: 17972956
Nocentini G, Riccardi C. GITR: a modulator of immune response and inflammation. Adv Exp Med Biol. 2009;647:156–73.
pubmed: 19760073
Mohr A, Zwacka R. Stem cell regulation by death ligands and their use in cell therapy. In: Micheau O, editor. TRAIL, fas ligand, TNF and TLR3 in cancer resistance to targeted anti-cancer therapeutics. Cham: Springer; 2017. p. 107–29.
Borysenko CW, García-Palacios V, Griswold RD, Li Y, Iyer AK, Yaroslavskiy BB, Sharrow AC, Blair HC. Death receptor-3 mediates apoptosis in human osteoblasts under narrowly regulated conditions. J Cell Physiol. 2006;209:1021–8.
pubmed: 16986165
Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA, Miller JB, Burkly LC, Zheng TS. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 2006;25:5826–39.
pubmed: 17124496
pmcid: 1698888
Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, Knight B. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology. 2010;52:291–302.
pubmed: 20578156
Le Gallo M, Poissonnier A, Blanco P, Legembre P. CD95/Fas, non-apoptotic signaling pathways, and kinases. Front Immunol. 2017;8:1–11.
Saile B, Knittel T, Matthes N, Schott P, Ramadori G. CD95/CD95L-mediated apoptosis of the hepatic stellate cell A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol. 1997;151:1265–72.
pubmed: 9358752
pmcid: 1858076
Cartier F, Marcq I, Douam F, Ossart C, Regnier A, Debuysscher V, Lavillette D, Bouhlal H. The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. PLoS ONE. 2014;9:1–10.
Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Characterization and functionality of the CD200–CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett. 2012;146:50–6.
pubmed: 22575528
Amati E, Perbellini O, Rotta G, Bernardi M, Chieregato K, Sella S, Rodeghiero F, Ruggeri M, Astori G. High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources. Stem Cell Res Ther. 2018;9:1–11.
Borrego F. The CD300 molecules: an emerging family of regulators of the immune system. Blood. 2013;121:1951–60.
pubmed: 23293083
pmcid: 3596959
Powell MD, Read KA, Sreekumar BK, Oestreich KJ. Ikaros zinc finger transcription factors: regulators of cytokine signaling pathways and CD4+ T helper cell differentiation. Front Immunol. 2019;10:1–11.